Sex-dependent modulation of treatment response

Dialogues in Clinical Neuroscience

Volumn 6, Issue 1, 2004, Pages 39-51

  Rubinow, David R ^a,b   Moore, Molly ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MSC 1276 ^*  (United States)

Author keywords

Antidepressant; Neuroleptic; Pharmacodynamics; Pharmacokinetics; Psychotropic drug; Sex

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MOCLOBEMIDE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PHENELZINE; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; SERTRALINE; THIORIDAZINE; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG; ZIPRASIDONE;

ACCURACY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PSYCHOPHARMACOTHERAPY; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 1842510712     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (201)

1. Phoenix CH, Goy RW, Gerall AA, Young WC. Organizing action of prenatally administered testosterone propionate on the tissues mediating mating behavior in the female guinea pig. Endocrinology. 1959;65:369-382.
2. Pfaff DW. Morphological changes in the brains of adult male rats after neonatal castration. J Endocrinol. 1966;36:415-416.
3. Nottebohm F, Arnold AP. Sexual dimorphism in vocal control areas of the songbird brain. Science. 1976;194:211-213.
4. Raisman G, Field PM. Sexual dimorphism in the preoptic area of the rat. Science. 1971;173:731-733.
5. Raisman G, Field PM. Sexual dimorphism in the neuropil of the preoptic area of the rat and its dependence on neonatal androgen. Brain Res. 1973;54:1-29.
6. Gorski RA, Gordon JH, Shryne JE, Southam AM. Evidence for a morphological sex difference within the medial preoptic area of the rat brain. Brain Res. 1978;148:333-346.
7. Rainbow TC, Parsons B, McEwen BS. Sex differences in rat brain oestrogen and progestin receptors. Nature. 1982;300:648-649.
8. Kendall DA, Stancel GM, Enna SJ. Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science. 1981;211:1183-1185.
9. Luine VN, McEwen BS. Sex differences in cholinergic enzymes of diagonal band nuclei in the rat preoptic area. Neuroendocrinology. 1983;36:475-482.
10. Zhang L, Li PP, Feng X, et al. Sex-related differences in neuronal cell survival and signaling in rats. Neurosci Lett. 2003;337:65-68.
11. Zhang L, Li B, Zhao W, et al. Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. Mol Brain Res. 2002;103:1-11.
12. Grossman MI, Kirsner JB, Gillespie IE. Basal and histalog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology. 1963;45:14-26.
13. Tahir H, Sumii K, Haruma K, et al. A statistical evaluation on the age and sex distribution of basal serum gastrin and gastric acid secretion in subjects with or without peptic ulcer disease. Hiroshima J Med Sci. 1984;33:125-130.
14. Kekki M, Samloff IM, Ihamaki T, Varis K, Siurala M. Age- and sex-related behaviour of gastric acid secretion at the population level. Scand J Gastroenterol. 1982;17:737-743.
15. Poulsen J, Lovgreen NA, Amdrup E. Fasting and food-stimulated serum gastrin concentration in 151 duodenal ulcer patients and 41 non-dyspeptic volunteers. Significant sex differences. Scand J Gastroenterol. 1986;21:881-885.
16. Lindahl A, Ungell AL, Knutson L, Lennernes H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res. 1997;14:497-502.
17. Feldman M, Richardson CT, Walsh JH. Sex-related differences in gastrin release and parietal cell sensitivity to gastrin in healthy human beings. J Clin Invest. 1983;71:715-720.
18. Dressman JB, Berardi RR, Dermentzoglou LC, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7:756-761.
19. Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin Physiol. 2001;21:253-259.
20. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol. 2003;38:36-42.
21. Madsen JL. Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci. 1992;37:1548-1553.
22. Nimmo WS. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet. 1976;1:189-203.
23. Hermansson G, Sivertsson R. Gender-related differences in gastric emptying rate of solid meals. Dig Dis Sci. 1996;41:1994-1998.
24. Knight LC, Parkman HP, Brown KL, et al. Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. Am J Gastroenterol. 1997;92:968-975.
25. Datz FL, Christian PE, Moore J. Gender-related differences in gastric emptying. J Nucl Med. 1987;28:1204-1207.
26. Bennink R, Peeters M, Van den Maegdenbergh V, et al. Evaluation of small-bowel transit for solid and liquid test meal in healthy men and women. Eur J Nucl Med. 1999;26:1560-1566.
27. Bennink R, Peeters M, Van den Maegdenbergh V, et al. Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med. 1998;25:1293-1299.
28. Notivol R, Carrio I, Cano L, Estorch M, Vilardell F. Gastric emptying of solid and liquid meals in healthy young subjects. Scand J Gastroenterol. 1984;19:1107-1113.
29. Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989;96:11-17.
30. Gryback P, Hermansson G, Lyrenas E, et al. Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. Eur J Nucl Med. 2000;27:647-655.
31. Caballero-Plasencia AM, Valenzuela-Barranco M, Martin-Ruiz JL, Herrerias-Gutierrez JM, Esteban-Carretero JM. Are there changes in gastric emptying during the menstrual cycle? Scand J Gastroenterol. 1999;34:772-776.
32. Wedmann B, Schmidt G, Wegener M, et al. Effects of age and gender on fat-induced gallbladder contraction and gastric emptying of a caloric liquid meal: a sonographic study. Am J Gastroenterol. 1991;86:1765-1770.
33. Klotz U. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet. 1976;1:204-218.
34. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1996;21:123-128.
35. Hashimoto S, Miwa M, Akasofu K, Nishida E. Changes in 40 serum proteins of post-menopausal women. Maturitas. 1991;13:23-33.
36. Blain PG, Mucklow JC, Rawlins MD, et al. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol. 1985;20:500-502.
37. Kishino S, Nomura A, Itoh S, et al. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol. 2002;58:621-628.
38. Feely J, Grimm T. A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians. Br J Clin Pharmacol. 1991;31:551-552.
39. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactant in postmenopausal women. Arterioscl Throm Vas Biol. 1997;17:1822-1829.
40. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull. 1997;33:235-241.
41. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001;33:161-235.
42. Kishino S, Nomura A, Di ZS, et al. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol. 1995;35:510-514.
43. Keefe D, Yee Y, Kates R. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther. 1981;29:21-26.
44. Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther. 2000;68:130-142.
45. Report to the Medical Research Council by its Clinical Psychiatry Committee. Clinical trial of the treatment of depressive illness. BMJ. 1965;1:881-886.
46. Björntorp P, Bengtsson C, Blohmé G, et al. Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism. 1971;20:927-935.
47. Novak LP. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J Gerontol. 1972;27:438-443.
48. Bickel WK, Oliveto AH, Kamien JB, Higgins ST, Hughes JR. A novel response procedure enhances the specificity and sensitivity of a triazolam discrimination in humans. J Pharmacol Exp Ther. 1993;264:360-367.
49. Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002;12:473-478.
50. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992;52:643-658.
51. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis. 1992;13:1561-1568.
52. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996;18:254-262.
53. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9:131-144.
54. Jennings TS, Nafziger AN, Davidson L, Bertino JS, Jr. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med. 1993;122:208-216.
55. Nafziger AN, Bertino JS, Jr. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol. 1989;37:97-100.
56. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-218.
57. Ou-Yang DS, Huang SL, Wang W, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol. 2000;49:145-151.
58. Zaigler M, Rietbrock S, Szymanski J, et al. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther. 2000;38:235-244.
59. Pantuck EJ, Kuntzman R, Conney AH. Decreased concentration of phenacetin in plasma of cigarette smokers. Science. 1972;175:1248-1250.
60. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991;50:508-519.
61. Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol. 1998;53:361-367.
62. 13C]caffeine breath test: influence of gender, cigarette smoking and oral contraceptives intake. Isotopes Environ Health Stud. 2002;38:71-77.
63. Anderson GD. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. J Gend Specif Med. 2002;5:25-33.
64. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 2003;49:542-551.
65. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-121.
66. Lin Y, Anderson GD, Kantor E, Ojemann LM, Wilensky AJ. Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol. 1999;39:578-582.
67. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol. 1999;39:275-280.
68. Kashuba AD, Nafziger AN, Kearns GL, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998;8:403-410.
69. Belle DJ, Callaghan JT, Gorski JC, et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol. 2002;53:67-74.
70. Bartoli A, Xiaodong S, Gatti G, et al. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit. 1996;18:586-591.
71. Campbell EA, Linton EA, Wolfe CD, et al. Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition. J Clin Endocrinol Metab. 1987;64:1054-1059.
72. Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med. 1980;95:603-608.
73. Labbe L, Sirois C, Pilote S, et al. Effects of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics. 2000;10:425-438.
74. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51:169-173.
75. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55:177-184.
76. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62:400-407.
77. Llerena A, Cobaleda J, Martinez C, Benitez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet. 1996;21:129-138.
78. McCune JS, Lindley C, Decker JL, et al. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol. 2001;41:723-731.
79. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001;15:897-918.
80. Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics. 1995;5:64-71.
81. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29:192-209.
82. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics. 2002;12:221-225.
83. Scripture C, Pieper J. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40:263-281.
84. Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002;194:267-273.
85. Wesson LG. Renal hemodynamics in physiological states. Physiology of the Human Kidney. New York, NY: Grune and Stratton; 1969:96-108.
86. James GD, Sealey JE, Alderman M, et al. A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens. 1988;1:124-131.
87. Slack TK, Wilson DM. Normal renal function: CIN and CPAH in healthy donors before and after nephrectomy. Mayo Clin Proc. 1976;51:296-300.
88. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000;37:49-59.
89. Masarei JRL. Validity of corrections for creatinine excretion and creatinine clearance. N Z Med J. 1975;82:197-198.
90. Holazo AA, Winkler MB, Patel IH. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol. 1988;28:1040-1045.
91. Baumgartner MG, Cautreels W, Langenbahn H. Biotransformation and pharmacokinetics of tetrazepam in man. Arzneimittelforschung Drug Res. 1984;34:724-729.
92. Kristjansson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm Nord. 1991;3:249-250.
93. van Steveninck AL, Wallnofer AE, Schoemaker RC, et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol. 1997;44:267-275.
94. Smith RB, Divoll M, Gillespie WR, Greenblatt DJ. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J Clin Psychopharmacol. 1983;3:172-176.
95. Shader RI, Greenblatt DJ, Ciraulo DA, et al. Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology. 1981;75:193-197.
96. Divoll M, Greenblatt DJ, Ochs HR, Shader RI. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg. 1983;62:1-8.
97. Ochs HR, Otten H, Greenblatt DJ, Dengler HJ. Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig Dis Sci. 1982;27:225-230.
98. Greenblatt DJ, Divoll MK, Abernethy DR, et al. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. Pharmacology. 1989;38:327-334.
99. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of temazepam. J Pharm Sci. 1981;70:1104-1107.
100. Greenblatt DJ, Harmatz JS, Von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther. 2000;293:435-443.
101. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980;215:86-91.
102. Greenblatt DJ, Abernety DR, Locniskar A, et al. Age, sex, and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther. 1985;38:697-703.
103. Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987;41:562-570.
104. Ochs HR, Greenblatt DJ, Otten H. Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr. 1981;59:899-903.
105. Yeates RA, Laufen H, Rader K, Leitold M. Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. Arzneimittelforschung. 1986;36:138-140.
106. Greenblatt DJ, Abernety DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61:27-35.
107. Divoll M, Greenblatt DJ. Effect of age and sex on lorazepam protein binding. J Pharm Pharmacol. 1982;34:122-123.
108. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. Diazepam disposition determinants. Clin Pharmacol Ther. 1980;27:301-312.
109. Giles HG, Sellers EM, Naranjo CA, Frecker RC, Greenblatt DJ. Disposition of intravenous diazepam in young men and women. Eur J Clin Pharmacol. 1981;20:207-213.
110. MacLeod SM, Giles HG, Bengert B, Liu FF, Sellers EM. Age- and gender-related differences in diazepam pharmacokinetics. J Clin Pharmacol. 1979; 19:15-19.
111. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991;50:404-409.
112. Greenblatt DJ, Shader RI, Franke K, et al. Kinetics of intravenous chlordiazepoxide: sex differences in drug distribution. Clin Pharmacol Ther 1977; 22:893-903.
113. Roberts RK, Desmond PV, Wilkinson GR, Schenker S. Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther. 1979;25:826-831.
114. Routledge PA, Stargel WW, Kitchell BB, Barchowsky A, Shand DG. Sex-related differences in the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol. 1981;11:245-250.
115. Giles HG, Roberts EA, Orrego H, Sellers EM. Disposition of intravenous propylthiouracil. J Clin Pharmacol. 1981;21:466-471.
116. Stoehr GP, Kroboth PD, Juhl RP, et al. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984;36:683-690.
117. Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther. 1985;38:525-532.
118. McAuley JW, Friedman CI. Influence of endogenous progesterone on alprazolam pharmacodynamics. J Clin Psychopharmacol. 1999;19:233-239.
119. Rukstalis M, de Wit H. Effects of triazolam at three phases of the menstrual cycle. J Clin Psychopharmacol. 1999;19:450-458.
120. Kamimori GH, Sirisuth N, Greenblatt DJ, Eddington ND. The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. J Clin Pharmacol. 2000;40:739-744.
121. Bayliss PF, Case DE. Blood level studies with viloxazine hydrochloride in man. Br J Clin Pharmacol. 1975;2:209-214.
122. Maguire KP, Norman TR, McIntyre I, Burrows GD. Clinical pharmacokinetics of dothiepin single-dose kinetics in patients and prediction of steady-state concentrations. Clin Pharmacokinet. 1983;8:179-185.
123. Barbhaiya RH, Shukla UA, Natarajan CS, et al. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther. 1995;58:390-398.
124. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987;42:193-200.
125. Lachatre G, Piva C, Riche C, et al. Single-dose pharmacokinetics of amineptine and of its main metabolite in healthy young adults. Fundam Clin Pharmacol. 1989;3:19-26.
126. Vandel B, Vandel S, Jounet JM, Blum D. Pharmacokinetics of viloxazine hydrochloride in man. Eur J Drug Metab Pharmacokinet. 1982;7:65-68.
127. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996;16:915-923.
128. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001;41:770-778.
129. Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol. 1995;49:221-228.
130. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol. 1996;16:19-25.
131. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;32:22-30.
132. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol. 1991;6(suppl 2):11-21.
133. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-743.
134. Amsterdam JD, Fawcett J, Qutkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:963-969.
135. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol. 2000;49:15S-20S.
136. Simpson GM, Yadalam KG, Levinson DF, et al. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol. 1990;10:417-421.
137. Wong SL, Cao G, Mack RJ, Granneman GR. Pharmacokinetics of sertin-dole in healthy young and elderly male and female subjects. Clin Pharmacol Ther. 1997;62:157-164.
138. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40:101-104.
139. Jerling M, Merle Y, Mentre F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997;44:447-453.
140. Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991;11:296-301.
141. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
142. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999;60:36-40.
143. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl). 1989;99(suppl):S38-S40.
144. Jann MW, Crabtree BL, Pitts WM, Lam YWF, Carter JG. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology. 1997;36:32-36.
145. Fabrazzo M, Esposito G, Fusco R, Maj M. Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology. 1996;124:197-200.
146. Kelly SJ, Ostrowski NL, Wilson MA. Gender differences in brain and behavior: hormonal and neural bases. Pharmacol Biochem Behav. 1999;64:655-664.
147. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209-216.
148. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry. 1977;34:197-204.
149. Wilson IC, Rabon AM, Buffaloe WJ. Imipramine therapy in depressive syndromes: prediction of therapeutic outcome. Psychosomatics. 1967;8:203-207.
150. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis. 1974;159:120-130.
151. Frank E, Carpenter LL, Kupfer DJ. Sex differences in recurrent depression: are there any that are significant? Am J Psychiatry. 1988;145:41-45.
152. Abraham HC, Kanter VB, Rosen I, Standen JL. A controlled clinical trial of imipramine (tofranil) with out-patients. Br J Psychiatry. 1963;109:286-293.
153. Imlah NW, Fahy PT, Harrington JA. A comparison of two antidepressant drugs. Psychopharmacologia. 1964;6:472-474.
154. Asberg M, Cronholm B, Sjoqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ. 1971;3:331-334.
155. Walker JM, Bowen WD, Atkins ST, Hemstreet MK, Coy DH. μ-Opiate binding and morphine antagonism by octapeptide analogs of somatostatin. Peptides. 1987;8:869-875.
156. Resiby N, Gram LF, Bech P, et al. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology. 1977;54:263-272.
157. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-1452.
158. Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002;36:384-391.
159. Lewis-Hall FC, Wilson MG, Tepner RG, Koke SC. Fluoxetine vs tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997;6:337-343.
160. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59:233-239.
161. Frank E, Thase ME, Spanier CA, Reynolds CF, III, Kupfer DJ. Gender-specific response to depression treatment. J Gend Specif Med. 1999;2:40-44.
162. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol. 2001;11:227-232.
163. Burns RA, Lock T, Edwards DR, et al. Predictors of response to amine-specific antidepressants. J Affect Disord. 1995;35:97-106.
164. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
165. Quitkin FM, Stewart JW, McGrath PJ, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry. 2002;159:1848-1854.
166. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 1986;17:87-95.
167. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360-1367.
168. Davidson JR, Giller EL, Zisook S, Helms MJ. Predictors of response to monoamine oxidase inhibitors: do they exist? Eur Arch Psychiatry Clin Neurosci. 1991;241:181-186.
169. Secunda SK, Katz MM, Swann A, et al. Mania. Diagnosis, state measurement and prediction of treatment response. J Affect Disord. 1985;8:113-121.
170. Viguera AC, Tondo L, Baldessarini RJ. Sex differences in response to lithium treatment. Am J Psychiatry. 2000;157:1509-1511.
171. Viguera AC, Baldessarini RJ, Tondo L. Response to lithium maintenance treatment in bipolar disorders: comparison of women and men. Bipolar Disord. 2001;3:245-252.
172. Denber HCB, Bird EG. Chlorpromazine in the treatment of mental illness. IV: final results with analysis of data on 1523 patients. Am J Psychiatry. 1957;113:972-978.
173. Chouinard G, Annable L. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology. 1982;76:13-19.
174. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Arch Gen Psychiatry. 1974;31:609-618.
175. Goldberg SC, Scholler NR, Davidson EM, Kayce MM. Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia. 1966;9:31-47.
176. Kolakowska T, Williams AO, Jambor K, Ardern M. Schizophrenia with good and poor outcome. III. Neurological "soft" signs, cognitive impairment and their clinical significance. Br J Psychiatry. 1985;146:348-357.
177. Meltzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 1983;9:271-283.
178. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
179. Goldstein JM, Cohen LS, Horton NJ, et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.
180. Goldstein MJ, Rodnick EH, Evans JR, May PR, Steinberg MR. Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry. 1978;35:1169-1177.
181. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50:369-376.
182. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic-patients. Am J Psychiatry. 1995;152:698-703.
183. Glick M, Mazure CM, Bowers MB, Zigler E. Premorbid social competence and the effectiveness of early neuroleptic treatment. Compr Psychiatry. 1993;34:396-401.
184. Pinals DA, Malhotra AK, Missar CD, Pickar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr Res. 1996;22:215-222.
185. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry. 2001;46:534-541.
186. Jeste DV, Linnoila M, Wagner RL, Wyatt RJ. Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacology. 1982;76:377-380.
187. Szymanski S, Lieberman J, Pollack S, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996;39:249-254.
188. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry. 1994;55:126-128.
189. Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999;156:1744-1750.
190. Young MA, Meltzer HY. The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements. Schizophr Bull. 1980;6:88-101.
191. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14-20.
192. Zito JM, Craig TJ, Wanderling J, Siegel C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry. 1987;144:778-782.
193. Magharious W, Goff DC, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 1998;77:159-166.
194. Jeste DV, Lindamer LA, Evans J, Lacro JP. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull. 1996;32:243-251.
195. Chouinard G, Annable L, Steinberg S. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol. 1986;6:21-26.
196. Riecher-Rossler A, Hafner H. Schizophrenia and oestrogens-is there an association? Eur Arch Psychiatry Clin Neurosci. 1993;242:323-328.
197. Salokangas RK. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr Res. 1995;16:7-16.
198. Seeman MV. Interaction of sex, age and neuroleptic dose. Compr Psychiatry. 1983;24:125-128.
199. Riecher-Rossler A, Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta PsychiatrScand Suppl. 2000;102:58-62.
200. Committee on Understanding the Biology of Sex and Gender Differences. Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington, DC: National Academy Press; 2001:1-8.
201. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:291-293.